Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

AUSTIN — Attorney General Ken Paxton sued major pharmaceutical makers and other companies Thursday, alleging they violated ...

One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years ...

Danish drugmaker Novo Nordisk said on Tuesday it has mitigation plans in place to minimize or prevent any disruption to its ...

The company is expected to present critical results from a trial of its CagriSema weight-loss injection in the fourth quarter ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

In terms of liquidity and interest, the mean open interest for Novo Nordisk options trades today is 703.94 with a total ...

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $118.01, denoting a -0.89% change from the preceding trading day.

"Pharmacy middlemen" are to blame for the high cost of drugs like Wegovy and Ozempic, according to Novo Nordisk's CEO. Is ...